Challenges and Opportunities for Medical Directors in Pathology and Laboratory Medicine Standardization, Integration, and Innovation

被引:10
作者
Hernandez, James S. [1 ]
Dale, Jane C. [2 ]
Bennet, Kevin E. [3 ]
Varkey, Prathibha [4 ]
机构
[1] Mayo Clin, Lab Serv, Div Clin Core, Rochester, MN USA
[2] Mayo Clin, Mayo Med Labs, Rochester, MN USA
[3] Mayo Clin, Div Engn & Technol Serv, Rochester, MN USA
[4] Mayo Clin, Div Prevent Occupat & Aerosp Med, Rochester, MN USA
关键词
Innovation; Integration; Laboratory medicine; Medical directors; Pathology; Standardization; PROSTATE-CANCER; ANALYTIC BIAS;
D O I
10.1309/AJCPSB4AL5EHAWTC
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Because the practice of pathology and laboratory medicine evolves rapidly, laboratory medical directors must constantly introduce new tests and services and continue to provide consistent, reliable results for existing tests. Innovations in laboratory medicine are frequently introduced, and the number of commercial vendors of test kits and reagents increases yearly. These innovations, however, may pose barriers to standardization and integration of laboratories and to interpretation of results generated by different laboratories. We propose a practical framework for medical directors to address the seemingly contradictory challenges of standardizing and integrating while simultaneously providing the flexibility to introduce innovations. We recommend initiating standardization first, then integration, while maintaining flexibility for innovation. As organizations strive to create effective processes to enhance value, the role of the laboratory medical director will become critical in resolving the natural tension between standardization/integration and innovation in laboratory medicine and pathology.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 2000, ONCOLOGY-BASEL, V14, P277
[2]  
[Anonymous], 2000, ONCOLOGY WILLISTONPA, V14, P280
[3]  
[Anonymous], MAN CREAT INN
[4]  
[Anonymous], 2000, ONCOLOGY-BASEL, V14, P267
[5]   Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients [J].
Brown, RE .
EXPERT REVIEW OF PROTEOMICS, 2005, 2 (03) :337-348
[6]   SELECTION OF OPTIMAL PROSTATE-SPECIFIC ANTIGEN CUTOFFS FOR EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES [J].
CATALONA, WJ ;
HUDSON, MA ;
SCARDINO, PT ;
RICHIE, JP ;
AHMANN, FR ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 152 (06) :2037-2042
[7]  
College of American Pathologists, 2009, OV COLL AM PATH CANC
[8]   The role of the medical laboratory [J].
Friedberg, Richard C. ;
Rauch, Carol A. .
CLINICS IN LABORATORY MEDICINE, 2007, 27 (04) :719-+
[9]   Managing transferability of laboratory data [J].
Guidi, Gian Cesare ;
Lippi, Giuseppe ;
Solero, Giovanni Pietro ;
Poli, Giovanni ;
Plebani, Mario .
CLINICA CHIMICA ACTA, 2006, 374 (1-2) :57-62
[10]  
Hernandez JS, 2003, ARCH PATHOL LAB MED, V127, P440